

[280] NOVEL FIRST-IN-CLASS INHIBITORS OF PROTEIN DEGRADATION - AN UNFOLDING STORY

Ori Kalid¹, Ira Gotliv¹, Einat Levy-Apter¹, Danit Finkelshtein-Beker¹, Marina Cherniavsky-Lev¹, ¹ Pi Therapeutics Ltd.

ABSTRACT TEMPLATE for Company Presentations

Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:

- **Investment Rational**
Pi Therapeutics is a preclinical pharmaceutical company developing innovative first-in-class small molecules targeting the protein degradation machinery. The company is focusing on relapsed/refractory multiple myeloma (RR/MM) as a first indication, with future expansion into additional hematologic malignancies and solid tumors.
- **Business Strategy**
Pi Therapeutics intends to move its drug candidates into clinical trials, and form partnership/s at later stages of development.
- **Core Technology**
Pi Therapeutics is developing novel chemical entities with a unique mechanism of action relevant to a variety of human tumors. PTX drugs display robust antitumor activity in animal models and overcome resistance to SOC MM drugs in cell lines as well as in bone marrow samples from MM patients.
- **Product Profile/Pipeline**
Pi Therapeutics' lead drug candidates are being developed towards clinical studies in late 2019.

Despite recent therapeutic advances, MM remains incurable and patients eventually relapse on all therapies. A substantial unmet need remains for relapsed and refractory patients that have limited therapeutic alternatives. Current preclinical data also suggests potential for addressing solid tumor indications with high unmet medical need, e.g. gynecological tumors.

- **What's Next?**
Pi Therapeutics is completing its 3-year incubation at the FutuRx Biotech Accelerator and raising series A funding to support preclinical and clinical development, as well as pipeline expansion.